English: Thank you very much, Llywydd, and thank you for the statement. I'm also very pleased to see the ground that's been gained in terms of the vaccination process in Wales. There are enthusiastic teams of vaccinators in all parts of the country, and I hear very positive reports of the experience that people have in accessing the vaccine, and that's to be welcomed. I will ask the first question emerging from that. Given that things are developing well at the moment, and I agree entirely with the Minister's comments that supply is the problem, not the number of vaccinators, but given that Novavax and Janssen are to come on stream soon, is it the Government's intention to move forward the target for vaccinating the whole population? I think we could now try and be more ambitious, if truth be told, and that's a very positive note. Now, although things are developing well, there are still concerns - concerns about the mix of Pfizer and AstraZeneca that we receive here in Wales. Of course, it would be easier if we had more of the vaccine that's easier to administer, and I'll ask the same question that I ask every week: can we have the data on how much of each vaccination is distributed to all nations and to all parts of Wales, in the spirit of transparency, so that we can identify any systematic problems? I know that the Minister suggested last week that he now agrees that it would be useful to have that data, and that he is going to try and get that data, so can we have an update on that? May I also make an appeal to the Government not to invite people to doubt the figures by failing to be entirely open in the statements that you make? We recall the Government saying that they were a little short of the target of 70 per cent of over-80s; well, that figure was 52.8 per cent, and that's a bit more than falling short. So, be transparent on the way that the figures are released. Likewise, we are seeing the older people's commissioner having to point out that she is concerned that a quarter of people in care homes still haven't been vaccinated. The figures as to where we are aren't included in the statement, aren't included in that information that's easiest to access by the public. So, be upfront about these figures so that we can see where we are. There is plenty of good news to focus on. Let us see where the problems are, too, so that everyone can see where those problems are. One question, if I may, specifically on the front-line ambulance service staff. It is a concern that a substantial number, perhaps, weren't willing to take the vaccination. So, could I have your comments on the concerns that that could put patients at risk? What's the Government's view on that? And a question that I asked last week, which I didn't receive a response to: the mRNA technology is new technology. The storage requirements mean that we need a new kind of infrastructure. It's very possible that we will become more and more reliant on that new vaccination technology, possibly to deal with new variants and so on. So, what consideration is now being given to investing in infrastructure that will make it easier to handle that kind of vaccine? Because it's possible that we will be far more reliant on it in future years.
Welsh: Diolch yn fawr iawn, Llywydd, a diolch am y datganiad. Dwi'n blês iawn i weld y tir sydd wedi cael ei ennill, yn sicr, o ran y broses frechu yng Nghymru. Mae yna dimau o frechwyr brwd iawn ym mhob cwr o'r wlad, ac dwi'n clywed adroddiadau positif iawn o'r profiad mae pobl yn ei gael wrth gael y brechiad yma. Mae hynny, wrth gwrs, i'w groesawu. Gwnaf i ofyn cwestiwn cyntaf yn deillio o hynny. Efo pethau'n mynd yn dda ar hyn o bryd - ac dwi'n cytuno'n llwyr efo sylwadau'r Gweinidog mai supply ydy'r broblem, nid pobl i wneud y brechu ar hyn o bryd - o ystyried bod y Novavax a Janssen yn dod tuag atom ni'n fuan iawn, ydy o'n fwriad gan y Llywodraeth i symud ymlaen y targed ar gyfer brechu'r boblogaeth gyfan? Erbyn hyn, dwi'n meddwl y gallwn ni drio bod yn fwy uchelgeisiol, mewn difri, ac mae hynny'n nodyn positif, dwi'n meddwl, i'w daro yn fan hyn. Er bod pethau'n mynd yn lled dda, mae yna bryderon o hyd - pryderon ynglŷn â'r mix o Pfizer ac AstraZeneca rydyn ni'n ei gael yma yng Nghymru. Wrth gwrs, mi fyddai'n haws pe bai gennym ni fwy o'r brechlyn sy'n haws i'w ddefnyddio. Felly, gaf i ofyn yr un cwestiwn â dwi'n gofyn bob wythnos? Plîs, gawn ni'r data ar faint o ba frechlyn sy'n cael ei rannu i bob gwlad a phob rhan o Gymru, yn ysbryd bod yn dryloyw, er mwyn gallu adnabod unrhyw broblemau yn y system? Dwi'n gwybod bod y Gweinidog wedi awgrymu'r wythnos diwethaf ei fod o rŵan yn cytuno y byddai'n ddefnyddiol cael hynny, a'i fod o am drio cael y data. Gawn ni ddiweddariad, os gwelwch yn dda? Gaf i hefyd apelio ar y Llywodraeth i beidio gwahodd pobl i amau'r ffigyrau drwy fethu â bod yn gwbl agored yn y datganiadau rydych chi'n eu gwneud? Rydyn ni'n cofio'r Llywodraeth yn dweud eu bod nhw ychydig yn brin o'r targed o 70 y cant o bobl dros 80; wel, 52.8 y cant oedd y ffigwr, ac mae hynny'n dipyn mwy nag ychydig yn brin. Byddwch yn dryloyw yn y ffordd mae'r ffigyrau yn cael eu datgan. Yn yr un ffordd eto, rydyn ni'n gweld y comisiynydd pobl hŷn, er enghraifft, yn gorfod pwyntio allan ei bod hi'n bryderus iawn bod chwarter y bobl mewn cartrefi gofal yn dal ddim wedi cael y brechiad. Dydy'r ffigyrau ynglŷn â lle rydyn ni arni ddim yn y datganiad, ddim yn yr wybodaeth sydd hawsaf i'w chanfod gan y cyhoedd, yn y diweddariad ar y broses frechu. Byddwch upfront ynglŷn â'r ffigyrau yma fel ein bod ni'n gallu gweld lle rydyn ni arni. Mae yna ddigon o newyddion da i ganolbwyntio arno fo. Gadewch i ni weld lle mae'r problemau hefyd, ac i bawb gael gweld lle mae'r problemau. Un cwestiwn gen i, os gaf i, yn benodol ynglŷn â staff gwasanaeth ambiwlans ar y rheng flaen. Mae'n bryder bod yna nifer sylweddol, o bosibl, ddim wedi bod yn fodlon derbyn y brechiad. A gaf i eich sylwadau chi ynglŷn â'r pryderon sydd wedi cael eu codi bod hynny yn gallu rhoi'r cleifion mewn perygl? Beth ydy barn y Llywodraeth ar hynny? A chwestiwn y gwnes i ofyn yr wythnos diwethaf, a ches i ddim ateb iddo fo: mae'r dechnoleg mRNA yn dechnoleg newydd. Mae'r gofynion storio ac ati yn golygu bod angen math newydd o isadeiledd. Mae'n bosib iawn y byddwn ni'n mynd yn fwy a mwy dibynnol ar y dechnoleg frechu newydd yma, o bosibl i ddelio efo variants newydd, ac yn y blaen. Beth ydy'r ystyriaeth sy'n cael ei rhoi rŵan i fuddsoddi mewn isadeiledd y bydd yn ei gwneud hi'n haws i handlo'r math yma o frechlyn? Achos, fel dwi'n dweud, mae'n bosibl iawn y byddwn ni'n dibynnu llawer mwy arno fo mewn blynyddoedd i ddod.